MA022-2037 / Myrio Therap - LARVOL DELTA

Development of a novel T cell engager for solid tumors presenting KRAS G12V mutant peptide in HLA-A*11:01 (AACR 2025) - "Our preclinical data support continued development of MA022-2037 for HLA-A*11:01-positive patients with KRAS G12V mutant tumors and IND-enabling studies are in progress. We anticipate delivery of a new precision immunotherapy for patients whose high unmet need is not currently addressed by molecularly targeted inhibitors."

IO biomarker • Oncology • Solid Tumor • KRAS